PeptidesDNA

Sample report— using simulated genetic data

Get Your Report — $99
PeptidesDNA Report

Your Genetic
Peptide Analysis

Based on 120 SNP markers, we scored 25 peptide compounds against your unique genetic profile. Here are your results.

117/120

SNPs Found

94%

Confidence

91/100

Top Match

Pathway Overview

88/100

Tissue Repair

72/100

Inflammation

81/100

Gut Integrity

76/100

GH/IGF-1 Axis

69/100

Neuroprotection

74/100

Longevity

Peptide Rankings

8 compounds scored

Your SNPs

CYP3A4 *1/*1 — Normal metabolizer
NOS3 rs1799983 G/T — Reduced NO production
COL5A1 rs12722 C/T — Elevated soft tissue risk

Interpretation

Normal compound metabolism with a genetically reduced nitric oxide pathway — exactly the pathway BPC-157 restores. Combined with elevated soft tissue vulnerability, this is your highest-confidence match.

Dose Adjustment

Standard dose — normal CYP3A4

Stacking Note

Pairs well with GHK-Cu (#2) for structural + surface repair.

This compound is available at peptide.engineering

View Compound →

CYP Metabolism Panel

Your liver uses these 7 CYP enzymes to process peptides and drugs. Your metabolizer status determines optimal dosing for every compound in this report.

CYP2D6
Normal Metabolizer
1.5
BPC-157SermorelinIpamorelin
CYP3A4
Normal Metabolizer
1.0
Most peptidesGHK-CuTB-500
CYP2C19
Rapid Metabolizer
2.0
Compound clearanceSome prodrugs
CYP2C9
Normal Metabolizer
1.0
NSAID interactionsWarfarin
CYP1A2
Intermediate Metabolizer
0.8
CaffeineTheophylline
CYP2B6
Normal Metabolizer
1.0
Niche substrates
CYP2E1
Normal Metabolizer
1.0
EthanolAcetaminophen

Suggested Protocol Order

Phase 1· Weeks 1–4

Foundation

GLP-2

Fix gut absorption first. Everything else you take works better after barrier integrity is restored.

Phase 2· Weeks 3–8

Recovery

BPC-157GHK-Cu

Layer structural repair once absorption is optimized. BPC-157 for tendons/gut, GHK-Cu for tissue regeneration.

Phase 3· Week 6+

Optimization

SemaxEpithalon

Add cognitive and longevity compounds once the foundation is solid. Lower priority, exploratory evidence.

About This Report

Evidence Tiers

Tier 1 (Clinical): Published pharmacogenomic trials with peptide or drug-class data. Highest confidence.

 

Tier 2 (Mechanistic): Known pathway biology applied to peptide pharmacology. Strong inference, not yet clinically validated for peptides specifically.

 

Tier 3 (Exploratory): Hypothesis-grade based on pathway overlap. Interesting but requires more research. Use with appropriate caution.

This was simulated data

Your CYP profile is unique.
Your scores will be different.

Upload your 23andMe or AncestryDNA file and see your actual peptide match scores in minutes.